Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world – Can elimination be maintained?

J. M. Prada, C. J.E. Metcalf, S. Takahashi, J. Lessler, A. J. Tatem, M. Ferrari

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction All six WHO regions currently have goals for measles elimination by 2020. Measles vaccination is delivered via routine immunization programmes, which in most sub-Saharan African countries reach children around 9 months of age, and supplementary immunization activities (SIAs), which target a wider age range at multi-annual intervals. In the absence of endemic measles circulation, the proportion of individuals susceptible to measles will gradually increase through accumulation of new unvaccinated individuals in each birth cohort, increasing the risk of an epidemic. The impact of SIAs and the financial investment they require, depend on coverage and target age range. Materials and methods We evaluated the impact of target population age range for periodic SIAs, evaluating outcomes for two different levels of coverage, using a demographic and epidemiological model adapted to reflect populations in 4 sub-Saharan African countries. Results We found that a single SIA can maintain elimination over short time-scales, even with low routine coverage. However, maintaining elimination for more than a few years is difficult, even with large (high coverage/wide age range) recurrent SIAs, due to the build-up of susceptible individuals. Across the demographic and vaccination contexts investigated, expanding SIAs to target individuals over 10 years did not significantly reduce outbreak risk. Conclusions Elimination was not maintained in the contexts we evaluated without a second opportunity for vaccination. In the absence of an expanded routine program, SIAs provide a powerful option for providing this second dose. We show that a single high coverage SIA can deliver most key benefits in terms of maintaining elimination, with follow-up campaigns potentially requiring smaller investments. This makes post-campaign evaluation of coverage increasingly relevant to correctly assess future outbreak risk.

Original languageEnglish (US)
Pages (from-to)1488-1493
Number of pages6
JournalVaccine
Volume35
Issue number11
DOIs
StatePublished - Mar 13 2017

Fingerprint

Immunization Programs
Measles
epidemiology
Immunization
immunization
Epidemiology
demographic statistics
vaccination
Demography
Vaccination
Disease Outbreaks
economic investment
Health Services Needs and Demand
Parturition
Population

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Prada, J. M. ; Metcalf, C. J.E. ; Takahashi, S. ; Lessler, J. ; Tatem, A. J. ; Ferrari, M. / Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world – Can elimination be maintained?. In: Vaccine. 2017 ; Vol. 35, No. 11. pp. 1488-1493.
@article{1d0686a8748a4d879e8a8a0fcaf36d28,
title = "Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world – Can elimination be maintained?",
abstract = "Introduction All six WHO regions currently have goals for measles elimination by 2020. Measles vaccination is delivered via routine immunization programmes, which in most sub-Saharan African countries reach children around 9 months of age, and supplementary immunization activities (SIAs), which target a wider age range at multi-annual intervals. In the absence of endemic measles circulation, the proportion of individuals susceptible to measles will gradually increase through accumulation of new unvaccinated individuals in each birth cohort, increasing the risk of an epidemic. The impact of SIAs and the financial investment they require, depend on coverage and target age range. Materials and methods We evaluated the impact of target population age range for periodic SIAs, evaluating outcomes for two different levels of coverage, using a demographic and epidemiological model adapted to reflect populations in 4 sub-Saharan African countries. Results We found that a single SIA can maintain elimination over short time-scales, even with low routine coverage. However, maintaining elimination for more than a few years is difficult, even with large (high coverage/wide age range) recurrent SIAs, due to the build-up of susceptible individuals. Across the demographic and vaccination contexts investigated, expanding SIAs to target individuals over 10 years did not significantly reduce outbreak risk. Conclusions Elimination was not maintained in the contexts we evaluated without a second opportunity for vaccination. In the absence of an expanded routine program, SIAs provide a powerful option for providing this second dose. We show that a single high coverage SIA can deliver most key benefits in terms of maintaining elimination, with follow-up campaigns potentially requiring smaller investments. This makes post-campaign evaluation of coverage increasingly relevant to correctly assess future outbreak risk.",
author = "Prada, {J. M.} and Metcalf, {C. J.E.} and S. Takahashi and J. Lessler and Tatem, {A. J.} and M. Ferrari",
year = "2017",
month = "3",
day = "13",
doi = "10.1016/j.vaccine.2017.02.008",
language = "English (US)",
volume = "35",
pages = "1488--1493",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11",

}

Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world – Can elimination be maintained? / Prada, J. M.; Metcalf, C. J.E.; Takahashi, S.; Lessler, J.; Tatem, A. J.; Ferrari, M.

In: Vaccine, Vol. 35, No. 11, 13.03.2017, p. 1488-1493.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world – Can elimination be maintained?

AU - Prada, J. M.

AU - Metcalf, C. J.E.

AU - Takahashi, S.

AU - Lessler, J.

AU - Tatem, A. J.

AU - Ferrari, M.

PY - 2017/3/13

Y1 - 2017/3/13

N2 - Introduction All six WHO regions currently have goals for measles elimination by 2020. Measles vaccination is delivered via routine immunization programmes, which in most sub-Saharan African countries reach children around 9 months of age, and supplementary immunization activities (SIAs), which target a wider age range at multi-annual intervals. In the absence of endemic measles circulation, the proportion of individuals susceptible to measles will gradually increase through accumulation of new unvaccinated individuals in each birth cohort, increasing the risk of an epidemic. The impact of SIAs and the financial investment they require, depend on coverage and target age range. Materials and methods We evaluated the impact of target population age range for periodic SIAs, evaluating outcomes for two different levels of coverage, using a demographic and epidemiological model adapted to reflect populations in 4 sub-Saharan African countries. Results We found that a single SIA can maintain elimination over short time-scales, even with low routine coverage. However, maintaining elimination for more than a few years is difficult, even with large (high coverage/wide age range) recurrent SIAs, due to the build-up of susceptible individuals. Across the demographic and vaccination contexts investigated, expanding SIAs to target individuals over 10 years did not significantly reduce outbreak risk. Conclusions Elimination was not maintained in the contexts we evaluated without a second opportunity for vaccination. In the absence of an expanded routine program, SIAs provide a powerful option for providing this second dose. We show that a single high coverage SIA can deliver most key benefits in terms of maintaining elimination, with follow-up campaigns potentially requiring smaller investments. This makes post-campaign evaluation of coverage increasingly relevant to correctly assess future outbreak risk.

AB - Introduction All six WHO regions currently have goals for measles elimination by 2020. Measles vaccination is delivered via routine immunization programmes, which in most sub-Saharan African countries reach children around 9 months of age, and supplementary immunization activities (SIAs), which target a wider age range at multi-annual intervals. In the absence of endemic measles circulation, the proportion of individuals susceptible to measles will gradually increase through accumulation of new unvaccinated individuals in each birth cohort, increasing the risk of an epidemic. The impact of SIAs and the financial investment they require, depend on coverage and target age range. Materials and methods We evaluated the impact of target population age range for periodic SIAs, evaluating outcomes for two different levels of coverage, using a demographic and epidemiological model adapted to reflect populations in 4 sub-Saharan African countries. Results We found that a single SIA can maintain elimination over short time-scales, even with low routine coverage. However, maintaining elimination for more than a few years is difficult, even with large (high coverage/wide age range) recurrent SIAs, due to the build-up of susceptible individuals. Across the demographic and vaccination contexts investigated, expanding SIAs to target individuals over 10 years did not significantly reduce outbreak risk. Conclusions Elimination was not maintained in the contexts we evaluated without a second opportunity for vaccination. In the absence of an expanded routine program, SIAs provide a powerful option for providing this second dose. We show that a single high coverage SIA can deliver most key benefits in terms of maintaining elimination, with follow-up campaigns potentially requiring smaller investments. This makes post-campaign evaluation of coverage increasingly relevant to correctly assess future outbreak risk.

UR - http://www.scopus.com/inward/record.url?scp=85012901932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012901932&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.02.008

DO - 10.1016/j.vaccine.2017.02.008

M3 - Article

C2 - 28216186

AN - SCOPUS:85012901932

VL - 35

SP - 1488

EP - 1493

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11

ER -